HAF017). A specific band was detected for EGFR at approximately 175 kDa (as indicated). This experiment was conducted under reducing conditions and using
Immunoblot Buffer Group 1." class="big_lightbox">
HAF017). A specific band was detected for EGFR at approximately 175 kDa (as indicated). This experiment was conducted under reducing conditions and using
Immunoblot Buffer Group 1." alt="Western blot shows lysates of HeLa human cervical epithelial carcinoma cell line and MDA-MB-231 human breast cancer cell line. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human EGFR Antigen Affinity-purified Polyclonal Antibody (Catalog # AF231) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog #
HAF017). A specific band was detected for EGFR at approximately 175 kDa (as indicated). This experiment was conducted under reducing conditions and using
Immunoblot Buffer Group 1." class="big_thumb" />
AF231) at 3ug/mL with overnight incubation at 4 degrees Celsius followed by incubation with anti-goat IgG VisUCyte HRP Polymer Antibody (Catalog #
VC004) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to keratinocytes. " class="big_lightbox">
AF231) at 3ug/mL with overnight incubation at 4 degrees Celsius followed by incubation with anti-goat IgG VisUCyte HRP Polymer Antibody (Catalog #
VC004) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to keratinocytes. " class="big_thumb" />
1095-ER) was serially diluted and captured by Goat Anti-Human EGFR Antigen Affinity-purified Polyclonal Antibody (Catalog # AF231) coated on a Clear Polystyrene Microplate (Catalog #
DY990). Goat Anti-Human EGFR Antigen Affinity-purified Polyclonal Antibody (Catalog #
AF231) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog #
DY998)" class="big_lightbox">
1095-ER) was serially diluted and captured by Goat Anti-Human EGFR Antigen Affinity-purified Polyclonal Antibody (Catalog # AF231) coated on a Clear Polystyrene Microplate (Catalog #
DY990). Goat Anti-Human EGFR Antigen Affinity-purified Polyclonal Antibody (Catalog #
AF231) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog #
DY998)" class="big_thumb" />
1095-ER) was serially diluted and captured by Goat Anti-Human EGFR Antigen Affinity-purified Polyclonal Antibody (Catalog #
AF231) coated on a Clear Polystyrene Microplate (Catalog #
DY990). Goat Anti-Human EGFR Antigen Affinity-purified Polyclonal Antibody (Catalog # AF231) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog #
DY998)" class="big_lightbox">
1095-ER) was serially diluted and captured by Goat Anti-Human EGFR Antigen Affinity-purified Polyclonal Antibody (Catalog #
AF231) coated on a Clear Polystyrene Microplate (Catalog #
DY990). Goat Anti-Human EGFR Antigen Affinity-purified Polyclonal Antibody (Catalog # AF231) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog #
DY998)" class="big_thumb" />
HAF017). A specific band was detected for EGFR at approximately 175 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." alt="Western blot shows lysates of HeLa human cervical epithelial carcinoma cell line and MDA-MB-231 human breast cancer cell line. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human EGFR Antigen Affinity-purified Polyclonal Antibody (Catalog # AF231) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for EGFR at approximately 175 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_thumb" />
HAF008). A specific band was detected for Phospho-EGFR (Y1173) at approximately 185 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." alt="Western blot shows lysates of A431 human epithelial carcinoma cell line untreated (-) or treated (+) with 100 µM pervanadate (PV) for 10 minutes. PVDF membrane was probed with 0.2 µg/mL of Rabbit Anti-Human Phospho-EGFR (Y1173) Antigen Affinity-purified Polyclonal Antibody, followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for Phospho-EGFR (Y1173) at approximately 185 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_thumb" />
HAF019). A specific band was detected for EGFR at approximately 170 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." alt="Western blot shows lysates of HeLa human cervical epithelial carcinoma cell line and MDA-MB-231 human breast cancer cell line. PVDF membrane was probed with 0.25 µg/mL of Goat Anti-Mouse EGFR Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1280) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for EGFR at approximately 170 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_thumb" />
236-EG) for 5 minutes. PVDF membrane was probed with 1 µg/mL of Human Phospho-EGFR (Y1068) Monoclonal Antibody (Catalog # MAB3570), followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for Phospho-EGFR (Y1068) at approximately 190 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." alt="Western blot shows lysates of A431 human epithelial carcinoma cell line untreated (-) or treated (+) with 100 ng/mL Recombinant Human EGF (Catalog # 236-EG) for 5 minutes. PVDF membrane was probed with 1 µg/mL of Human Phospho-EGFR (Y1068) Monoclonal Antibody (Catalog # MAB3570), followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for Phospho-EGFR (Y1068) at approximately 190 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_thumb" />
236-EG) for 5 minutes to induce tyrosine phosphorylation of EGF R. Lysates were serially diluted and analyzed by (A) IP-Western blot and (B) this DuoSet IC ELISA. IPs were done using an anti-EGF R monoclonal antibody and anti-mouse IgG agarose. Immunoblots were incubated with an HRP-conjugated anti-phospho-tyrosine monoclonal antibody (R&D Systems, Catalog #HAM1676) to detect phosphor-EGF R. Bands were visualized by chemiluminescent detection. Human Phospho-EGF R can be detected in this DuoSet IC ELISA by using approximately 2-4 times less lysate than is needed for a conventional IP-Western blot." alt="The human epidermoid carcinoma cell line, A431, was treated with 25 ng/mL recombinant human EGF (R&D Systems Catalog #236-EG) for 5 minutes to induce tyrosine phosphorylation of EGF R. Lysates were serially diluted and analyzed by (A) IP-Western blot and (B) this DuoSet IC ELISA. IPs were done using an anti-EGF R monoclonal antibody and anti-mouse IgG agarose. Immunoblots were incubated with an HRP-conjugated anti-phospho-tyrosine monoclonal antibody (R&D Systems, Catalog #HAM1676) to detect phosphor-EGF R. Bands were visualized by chemiluminescent detection. Human Phospho-EGF R can be detected in this DuoSet IC ELISA by using approximately 2-4 times less lysate than is needed for a conventional IP-Western blot." class="big_thumb" />
AB-108-C, open histogram), followed by Phycoerythrin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # 
NL001) and counterstained with DAPI (blue). Specific staining was localized to plasma membrane. View our protocol for 
VC004). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to plasma membrane. View our protocol for 
AF231) at 3ug/mL with overnight incubation at 4 degrees Celsius followed by incubation with anti-goat IgG VisUCyte HRP Polymer Antibody (Catalog # 
1095-ER) was serially diluted and captured by Goat Anti-Human EGFR Antigen Affinity-purified Polyclonal Antibody (Catalog # AF231) coated on a Clear Polystyrene Microplate (Catalog # 
1095-ER) was serially diluted and captured by Goat Anti-Human EGFR Antigen Affinity-purified Polyclonal Antibody (Catalog # ![Flow Cytometry: EGFR Antibody (DH8.3) - EGFRvIII [NBP2-50599] - An intracellular stain was performed on A431 cells with EGFR [DH8.3] Antibody NBP2-50599R (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 550.](http://images.novusbio.com/fullsize/EGFR-Antibody-DH8-3-EGFRvIII-Flow-Cytometry-NBP2-50599-img0002.jpg "Flow Cytometry: EGFR Antibody (DH8.3) - EGFRvIII [NBP2-50599] - An intracellular stain was performed on A431 cells with EGFR [DH8.3] Antibody NBP2-50599R (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 550.")
![Flow Cytometry: EGFR Antibody (DH8.3) - EGFRvIII [NBP2-50599] - An intracellular stain was performed on A431 cells with EGFR [DH8.3] Antibody NBP2-50599AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.](http://images.novusbio.com/fullsize/EGFR-Antibody-DH8-3-EGFRvIII-Flow-Cytometry-NBP2-50599-img0001.jpg)
![Flow Cytometry: Mouse Monoclonal EGFR Antibody (DH8.3) - EGFRvIII [NBP2-50599] - Analysis of glioblastoma cell lines using EGFR Antibody. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nbp2-50599_mouse-monoclonal-egfr-antibody-dh8-3-egfrviii-mutant-flow-cytometry-145202414346..png)
NL004) and counterstained with DAPI (blue). View our protocol for 
CTS005) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling if primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for 
VC003). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (
236-EG; filled histogram) then stained with Rabbit Anti-Human Phospho-EGFR (Y1173) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1095), followed by Phycoerythrin-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # 
236-EG) for 5 minutes, loaded at 0.2 mg/mL. A specific band was detected for Phospho-EGFR (Y1173) at approximately 265 kDa (as indicated) using 2 µg/mL of Rabbit Anti-Human Phospho-EGFR (Y1173) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1095). This experiment was conducted under reducing conditions and using the 66-440 kDa separation system." class="big_thumb" />
![Matrix Fibulin-1 regulates EGF dependent EGFR activation in Calu-1 . (A) Endogenous Fibulin-1 (WB: FBLN1) & GAPDH (WB: GAPDH) detected by WB in cell derived matrix (CDM before replating) made from control (CON), FBLN1C (1Ci) & FBLN1D (1Di) knockdown Calu-1 , grown with serum (5% FBS) for 72 h. Calu-1 replated on this CDM & grown for 18 h with serum [+18 h (5% FBS)] & levels of Fibulin-1 (WB: FBLN1) & GAPDH (WB: GAPDH) detected by WB in cell derived matrix (CDM after replating) & compared to those seen in CDM before replating. FBLN1C & FBLN1D isoforms detected in blots of knockdown lysates are marked by arrows. Blot is best representative of three independent experiments that gave similar results. (B) Representative individual migration tracks of Calu-1 adherent in the presence of serum growth factors (5% FBS) on CDM (made as detailed above) from control (CON-CDM), FBLN1C (1Ci-CDM), & FBLN1D (1Di-CDM) knockdown Calu-1 . (C) Accumulated distance, euclidean distance, velocity & directionality of 100 migrating (per experiment) & represented in the bar graphs as mean ± SE from eight independent experiments. p values calculated using one-way ANOVA & Tukey’s post hoc test & represented if found to be significant. (D,E) WB detection of EGFR phosphorylated on tyrosine 1173 (WB: pEGFR), total EGFR (WB: tEGFR) & GAPDH (WB: GAPDH) in Calu-1 plated on CDM (made as detailed above) from control (CON-CDM), FBLN1C (1Ci-CDM) & FBLN1D (1Di-CDM) knockdown (D) in the presence of serum growth factors (5% FBS) (E) on stimulation with EGF (100 ng/ml) for 5 min (+EGF) in serum deprived Calu-1 . Bar graphs represents mean ± SE of pEGFR to total EGFR ratio from 3 or 4 independent experiments as indicated. Statistical analysis of the data was done using the students t-test & p values are as shown. Image collected & cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32719793), licensed under a CC-BY license. Not internally tested by R&D Systems.](http://images.novusbio.com/fullsize/af1095_human-phospho-egfr-y1173-affinity-purified-pab-western-blot-12122025811818.jpg)
![Matrix Fibulin-1 regulates EGF dependent EGFR activation in Calu-1 . (A) Endogenous Fibulin-1 (WB: FBLN1) & GAPDH (WB: GAPDH) detected by WB in cell derived matrix (CDM before replating) made from control (CON), FBLN1C (1Ci) & FBLN1D (1Di) knockdown Calu-1 , grown with serum (5% FBS) for 72 h. Calu-1 replated on this CDM & grown for 18 h with serum [+18 h (5% FBS)] & levels of Fibulin-1 (WB: FBLN1) & GAPDH (WB: GAPDH) detected by WB in cell derived matrix (CDM after replating) & compared to those seen in CDM before replating. FBLN1C & FBLN1D isoforms detected in blots of knockdown lysates are marked by arrows. Blot is best representative of three independent experiments that gave similar results. (B) Representative individual migration tracks of Calu-1 adherent in the presence of serum growth factors (5% FBS) on CDM (made as detailed above) from control (CON-CDM), FBLN1C (1Ci-CDM), & FBLN1D (1Di-CDM) knockdown Calu-1 . (C) Accumulated distance, euclidean distance, velocity & directionality of 100 migrating (per experiment) & represented in the bar graphs as mean ± SE from eight independent experiments. p values calculated using one-way ANOVA & Tukey’s post hoc test & represented if found to be significant. (D,E) WB detection of EGFR phosphorylated on tyrosine 1173 (WB: pEGFR), total EGFR (WB: tEGFR) & GAPDH (WB: GAPDH) in Calu-1 plated on CDM (made as detailed above) from control (CON-CDM), FBLN1C (1Ci-CDM) & FBLN1D (1Di-CDM) knockdown (D) in the presence of serum growth factors (5% FBS) (E) on stimulation with EGF (100 ng/ml) for 5 min (+EGF) in serum deprived Calu-1 . Bar graphs represents mean ± SE of pEGFR to total EGFR ratio from 3 or 4 independent experiments as indicated. Statistical analysis of the data was done using the students t-test & p values are as shown. Image collected & cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32719793), licensed under a CC-BY license. Not internally tested by R&D Systems.](http://images.novusbio.com/fullsize/af1095_human-phospho-egfr-y1173-affinity-purified-pab-western-blot-12122025814110.jpg)
CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to developing muscle. View our protocol for 
HAF109). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system." class="big_thumb" />
236-EG, filled histogram) then stained with Human Phospho--EGFR (Y1068) Monoclonal Antibody (Catalog # MAB3570), followed by Phycoerythrin-conjugated Anti-Mouse IgG F(ab')2Secondary Antibody (Catalog # 
AF231)." class="big_thumb" />
1095-ER), human ErbB2/Fc Chimera (R&D Systems, Catalog #
344-ER) binds recombinant human EGF (![Immunocytochemistry/Immunofluorescence: EGFR Antibody [NBP1-84814] - Staining of human cell line A-431 shows positivity in plasma membrane. Antibody staining is shown in green.](http://images.novusbio.com/fullsize/EGFR-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-84814-img0006.jpg "Immunocytochemistry/Immunofluorescence: EGFR Antibody [NBP1-84814] - Staining of human cell line A-431 shows positivity in plasma membrane. Antibody staining is shown in green.")
![Immunohistochemistry-Paraffin: EGFR Antibody [NBP1-84814] - Staining of human placenta shows strong membranous positivity in trophoblastic cells.](http://images.novusbio.com/fullsize/EGFR-Antibody-Immunohistochemistry-Paraffin-NBP1-84814-img0017.jpg)
![Immunohistochemistry-Paraffin: EGFR Antibody [NBP1-84814] - Staining of human breast shows moderate cytoplasmic positivity in glandular cells.](http://images.novusbio.com/fullsize/EGFR-Antibody-Immunohistochemistry-Paraffin-NBP1-84814-img0015.jpg)
![Immunohistochemistry-Paraffin: EGFR Antibody [NBP1-84814] - Staining of human cerebellum shows no positivity in Purkinje cells as expected.](http://images.novusbio.com/fullsize/EGFR-Antibody-Immunohistochemistry-Paraffin-NBP1-84814-img0016.jpg)
![Immunohistochemistry-Paraffin: EGFR Antibody (31G7) [NBP2-45148] - Human Placenta stained with EGFR Monoclonal Antibody (31G7).](http://images.novusbio.com/fullsize/EGFR-Antibody-31G7-Immunohistochemistry-Paraffin-NBP2-45148-img0001.jpg "Immunohistochemistry-Paraffin: EGFR Antibody (31G7) [NBP2-45148] - Human Placenta stained with EGFR Monoclonal Antibody (31G7).")
![Protein Array: EGFR Antibody (31G7) [NBP2-45148] - Analysis of Protein Array containing more than 19,000 full-length human proteins using EGFR Antibody (31G7) Z- and S- Score: The Z-score represents the strength of a signal that a monoclonal antibody (Monoclonal Antibody) (in combination with a fluorescently-tagged anti-IgG secondary antibody) produces when binding to a particular protein on the HuProt(TM) array. Z-scores are described in units of standard deviations (SD's) above the mean value of all signals generated on that array. If targets on HuProt(TM) are arranged in descending order of the Z-score, the S-score is the difference (also in units of SD's) between the Z-score. S-score therefore represents the relative target specificity of a Monoclonal Antibody to its intended target. A Monoclonal Antibody is considered to specific to its intended target, if the Monoclonal Antibody has an S-score of at least 2.5.](http://images.novusbio.com/fullsize/EGFR-Antibody-31G7-Protein-Array-NBP2-45148-img0003.jpg)
![ELISA EGFR [Biotin]](http://images.novusbio.com/fullsize/dyc1854-2_human-total-egfr-duoset-ic-elisa-2-plate-elisa-1592020123548.jpg "ELISA EGFR [Biotin]")
AF231) Immunoblots were incubated with a biotinylated anti-EGF R polyclonal antibody (Catalog # 
![Western Blot: EGFR Antibody (CL0815) [NBP2-52952] - Lane 1: Marker [kDa], Lane 2: Human cell line A-431](http://images.novusbio.com/fullsize/EGFR-Antibody-CL0815-Western-Blot-NBP2-52952-img0004.jpg "Western Blot: EGFR Antibody (CL0815) [NBP2-52952] - Lane 1: Marker [kDa], Lane 2: Human cell line A-431")
![Immunohistochemistry-Paraffin: EGFR Antibody (CL0815) [NBP2-52952] - Staining of human ventricular cancer shows moderate membranous immunoreactivity in tumor cells.](http://images.novusbio.com/fullsize/EGFR-Antibody-CL0815-Immunohistochemistry-Paraffin-NBP2-52952-img0003.jpg)
![Immunohistochemistry-Paraffin: EGFR Antibody (CL0815) [NBP2-52952] - Staining of human placenta shows strong membranous positivity in trophoblast.](http://images.novusbio.com/fullsize/EGFR-Antibody-CL0815-Immunohistochemistry-Paraffin-NBP2-52952-img0001.jpg)
![Immunohistochemistry-Paraffin: EGFR Antibody (CL0815) [NBP2-52952] - Staining of human tonsil shows moderate membranous immunoreactivity in squamous epithelial cells.](http://images.novusbio.com/fullsize/EGFR-Antibody-CL0815-Immunohistochemistry-Paraffin-NBP2-52952-img0002.jpg)
